Compare OPK & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPK | IVA |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2011 | 2020 |
| Metric | OPK | IVA |
|---|---|---|
| Price | $1.49 | $4.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $1.60 | ★ $16.20 |
| AVG Volume (30 Days) | ★ 4.3M | 671.3K |
| Earning Date | 04-28-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $606,879,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.98 | $3.35 |
| 52 Week High | $1.73 | $7.98 |
| Indicator | OPK | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 62.44 | 57.98 |
| Support Level | $1.26 | $4.46 |
| Resistance Level | $1.55 | $4.94 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 87.63 | 65.31 |
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.